NCT05984927 - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2030

Conditions

Age-Related Macular Degeneration

Interventions

GENETIC

NG101 AAV gene therapy

Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector

Trial Locations (5)

RECRUITING

Cincinnati Eye Institute, Cincinnati

RECRUITING

Retina Consultants of Texas, Bellaire

RECRUITING

Vancouver Coastal Health Research Institute, Vancouver

RECRUITING

Sunnybrook Ophthalmology and Vision Services, Toronto

RECRUITING

Vitreous Retina Macula Specialists of Toronto, Toronto